This FDA clearance for the Magstim Horizon 3.0 and Inspire systems builds on the existing patient TMS clearances for adult patients, making it possible for physicians and nurse practitioners to treat ...

QRL-101-03 (NCT06532396) is a randomized, double-blind, placebo-controlled, multiple-ascending dose clinical trial evaluating the safety, tolerability, and PK of QRL-101 in up to 60 healthy ...

Results demonstrated statistically significant effects on biomarkers that predict ALS disease progression and severity Evidence of brain penetration, target engagement, and potential anti-seizure ...

Phoneme pairs and words were presented during a control condition and during transcranial magnetic stimulation targeted to inhibit or augment the EEG signal associated with specific articulatory ...

Motor function and electroencephalography (EEG) metrics were assessed before and after treatment. Overall FMA improvement showed no difference between groups, but the TMS-mild/moderate impairment ...

Stimulation parameters were personalized and identified using fMRI and TMS-EEG (see Fig. 1, panels A and B). Long-term memory was assessed by the face-name associative task (FNAT), requiring the ...

Brain responses to transcranial magnetic stimulation (TMS) can be recorded with electroencephalography (EEG) and comprise TMS-evoked potentials and TMS-induced oscillations. Repetitive TMS may entrain ...

Based on the above-reviewed evidence provided by EEG and TMS studies, we hypothesized that (1) P300 onset latency would track the speed of inhibitory control (SSRT) and (2) rIFG is causally related to ...